I found this comment particularly interesting:
"The NASH and oncology data sets form the basis of our forward-looking strategy for how CytoDyn will continue to pursue the molecule. We are also developing a longer-acting version of leronlimab with our partners at Oregon Health & Science University. It has been tested in animal models, including rhesus monkeys, and has been shown to remain active inside the body for up to 180 days; treated monkeys are highly resistant to HIV infection, even after repeat challenges on a weekly basis for months. These data are really exciting, and there is no reason this long-acting version cannot also be used for the treatment of solid tumors and NASH.
CytoDyn will continue developing both the short- and long-acting versions of leronlimab. The goal is to bundle these two molecules together and find a strategic partner that can help us advance to later-stage clinical development and commercialization."
"The NASH and oncology data sets form the basis of our forward-looking strategy for how CytoDyn will continue to pursue the molecule. We are also developing a longer-acting version of leronlimab with our partners at Oregon Health & Science University. It has been tested in animal models, including rhesus monkeys, and has been shown to remain active inside the body for up to 180 days; treated monkeys are highly resistant to HIV infection, even after repeat challenges on a weekly basis for months. These data are really exciting, and there is no reason this long-acting version cannot also be used for the treatment of solid tumors and NASH.
CytoDyn will continue developing both the short- and long-acting versions of leronlimab. The goal is to bundle these two molecules together and find a strategic partner that can help us advance to later-stage clinical development and commercialization."
9
CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
